Bayer Switches Focus Of Recursion AI Pact To Oncology
After streamlining its R&D strategy in the summer, Bayer’s rewritten pact with Recursion Pharmaceuticals looks like a vote of confidence in its AI-enabled drug discovery platform.
You may also be interested in...
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
As artificial intelligence-aided drug discovery gains momentum, Sanofi appears keen to hop onboard via a recent tie-up with leading Chinese AI company BioMap. But data challenges, a hard-to-define value proposition, concerns over data security and looming regulations are making others hesitant.
After a miserable third quarter the German group is cutting jobs and considering splitting up, but concrete decisions are thin on the ground.